Splash Beverage Group, Inc. entered into an addendum on July 28, 2026, to its exclusive global license agreement for CannEpil with Argent BioPharma Limited. The amendment expands the field of use to include veterinary applications and establishes a tiered royalty structure: 10% of net revenue from veterinary applications and 15% from human applications. Various deadlines under the original July 6, 2026 agreement were also extended. Splash intends to initially evaluate CannEpil for companion-animal oncology and chronic pain management, targeting canine indications through FDA Center for Veterinary Medicine pathways. The company is finalizing a strategic joint venture with an established cannabinoid pharmaceutical firm to lead this veterinary development program. Splash Beverage Group, Inc. operates in the cannabinoid health, wellness, and biopharmaceutical sector.
